Latest news

Filter by category:

FILTER: ALL CATEGORIESFilter by:

Latest news

07 May 2021

CEPI and Dynavax expand collaboration to increase supply of adjuvant for COVID-19 vaccines
Expanded agreement between CEPI and Dynavax will increase the supply of adjuvant available for CEPI-funded COVID-19 vaccine development programmes in 2021.

Read more

Read article

30 Apr 2021

UK support a vital first step in turning tide against future pandemics
The UK Government will host CEPI’s replenishment summit in 2022. This event will be the crucial moment for the world to take action to support our US$3.5 billion plan. 

Read more

30 Apr 2021

UK to host global summit with CEPI to speed up new vaccine development
The UK will host a fundraising summit in 2022 to support the work of CEPI.

Read more

13 Apr 2021

CEPI and the African Union join forces to boost African vaccine R&D and manufacturing
Collaboration forms a major part of CEPI’s longer term epidemic and pandemic strategy

Read more

09 Apr 2021

Do we need to update our tools assessing COVID-19 vaccine performance to work against the novel variants?
CEPI, the National Institute of Biological Standards and Control (NIBSC) and the World Health Organization (WHO) are on the search for partners to investigate.

Read more

08 Apr 2021

Covax reaches over 100 economies, 42 days after first international delivery
More than 38 million doses of vaccines from manufacturers AstraZeneca, Pfizer-BioNTech and Serum Institute of India (SII) have now been delivered.

Read more

31 Mar 2021

CEPI launches funding call to advance development of broadly protective coronavirus vaccines
Up to US$200 million in funding to be allocated for development of vaccines that provide broad protection against SARS-CoV-2 and betacoronaviruses.

Read more

30 Mar 2021

CEPI Board membership updates

Read more

Read article

18 Mar 2021

CEPI and University of Hong Kong expand partnership to develop intranasal COVID-19 vaccine candidate
CEPI will invest an additional $4.8m to fund the production of clinical trial materials, and the investigation of mucosal immune responses during a Phase 1 trial of the vaccine candidate.

Read more

10 Mar 2021

CEPI and VBI Vaccines collaborate to advance vaccine candidates against COVID-19 variants
Up to $33m of funding will support development of VBI’s enveloped virus-like particle (eVLP) vaccine candidates against COVID-19 variants of concern.

Read more

10 Mar 2021

CEPI launches plan to tackle risk of future pandemics and epidemics
US$3.5 billion replenishment strategy aims to cut vaccine development timeline for new pandemics by two-thirds to 100 days

Read more

©2021 CEPI. All rights reserved

This website uses cookies to improve functionality and performance. If you continue browsing the site, you consent to the use of cookies on this website. For details, see our Cookie Notice.